Site-specific expression of amine oxidases in breast cancer metastases

We aimed to evaluate the expression of amine oxidase-related proteins in metastatic breast cancer tissue and determine its clinical implication. A tissue microarray was constructed from a total of 126 metastatic breast tumors (31 bone metastases (24.6%), 36 brain metastases (28.6%), 11 liver metasta...

Full description

Bibliographic Details
Main Authors: Yoon Jin Cha, Woo Hee Jung, Ja Seung Koo
Format: Article
Language:English
Published: IOS Press 2018-05-01
Series:Tumor Biology
Online Access:https://doi.org/10.1177/1010428318776822
id doaj-b0c8c15740bb4f6685f0ef33ad549115
record_format Article
spelling doaj-b0c8c15740bb4f6685f0ef33ad5491152021-05-02T15:10:07ZengIOS PressTumor Biology1423-03802018-05-014010.1177/1010428318776822Site-specific expression of amine oxidases in breast cancer metastasesYoon Jin ChaWoo Hee JungJa Seung KooWe aimed to evaluate the expression of amine oxidase-related proteins in metastatic breast cancer tissue and determine its clinical implication. A tissue microarray was constructed from a total of 126 metastatic breast tumors (31 bone metastases (24.6%), 36 brain metastases (28.6%), 11 liver metastases (8.7%), and 48 lung metastases (38.1%)). Immunohistochemical staining for amine oxidase-related proteins (lysyl oxidase, diamine oxidase, and monoamine oxidase A and B) was performed. In metastatic breast cancer tissue, lysyl oxidase ( p  = 0.001), tumoral diamine oxidase ( p  = 0.003), stromal diamine oxidase ( p  = 0.047), and stromal monoamine oxidase B ( p  = 0.002) were differentially expressed in different metastatic sites. Bone metastases showed low expression of lysyl oxidase, tumoral diamine oxidase, and stromal diamine oxidase. We observed high expression of lysyl oxidase in brain metastases, tumoral diamine oxidase in liver metastases, stromal diamine oxidase in lung metastases, and stromal monoamine oxidase B in bone metastases. Lysyl oxidase positivity was associated with progesterone receptor negativity ( p  = 0.001), and monoamine oxidase A positivity was associated with human epidermal growth factor receptor-2 negativity ( p  = 0.003) and the luminal A subtype ( p  = 0.003). On univariate analysis shorter overall survival was associated with stromal diamine oxidase negativity ( p  = 0.008), especially in lung metastases ( p  = 0.025), and stromal monoamine oxidase B positivity ( p  < 0.001). Stromal monoamine oxidase B positivity was an independent prognostic factor for shorter overall survival in multivariate Cox analysis (hazard ratio, 4.069; 95% confidence interval, 1.649–10.04; p  = 0.002). Finally, in metastatic breast cancer, amine oxidase-related proteins were differentially expressed in a manner specific to metastatic site, and stromal monoamine oxidase B expression was correlated with prognosis.https://doi.org/10.1177/1010428318776822
collection DOAJ
language English
format Article
sources DOAJ
author Yoon Jin Cha
Woo Hee Jung
Ja Seung Koo
spellingShingle Yoon Jin Cha
Woo Hee Jung
Ja Seung Koo
Site-specific expression of amine oxidases in breast cancer metastases
Tumor Biology
author_facet Yoon Jin Cha
Woo Hee Jung
Ja Seung Koo
author_sort Yoon Jin Cha
title Site-specific expression of amine oxidases in breast cancer metastases
title_short Site-specific expression of amine oxidases in breast cancer metastases
title_full Site-specific expression of amine oxidases in breast cancer metastases
title_fullStr Site-specific expression of amine oxidases in breast cancer metastases
title_full_unstemmed Site-specific expression of amine oxidases in breast cancer metastases
title_sort site-specific expression of amine oxidases in breast cancer metastases
publisher IOS Press
series Tumor Biology
issn 1423-0380
publishDate 2018-05-01
description We aimed to evaluate the expression of amine oxidase-related proteins in metastatic breast cancer tissue and determine its clinical implication. A tissue microarray was constructed from a total of 126 metastatic breast tumors (31 bone metastases (24.6%), 36 brain metastases (28.6%), 11 liver metastases (8.7%), and 48 lung metastases (38.1%)). Immunohistochemical staining for amine oxidase-related proteins (lysyl oxidase, diamine oxidase, and monoamine oxidase A and B) was performed. In metastatic breast cancer tissue, lysyl oxidase ( p  = 0.001), tumoral diamine oxidase ( p  = 0.003), stromal diamine oxidase ( p  = 0.047), and stromal monoamine oxidase B ( p  = 0.002) were differentially expressed in different metastatic sites. Bone metastases showed low expression of lysyl oxidase, tumoral diamine oxidase, and stromal diamine oxidase. We observed high expression of lysyl oxidase in brain metastases, tumoral diamine oxidase in liver metastases, stromal diamine oxidase in lung metastases, and stromal monoamine oxidase B in bone metastases. Lysyl oxidase positivity was associated with progesterone receptor negativity ( p  = 0.001), and monoamine oxidase A positivity was associated with human epidermal growth factor receptor-2 negativity ( p  = 0.003) and the luminal A subtype ( p  = 0.003). On univariate analysis shorter overall survival was associated with stromal diamine oxidase negativity ( p  = 0.008), especially in lung metastases ( p  = 0.025), and stromal monoamine oxidase B positivity ( p  < 0.001). Stromal monoamine oxidase B positivity was an independent prognostic factor for shorter overall survival in multivariate Cox analysis (hazard ratio, 4.069; 95% confidence interval, 1.649–10.04; p  = 0.002). Finally, in metastatic breast cancer, amine oxidase-related proteins were differentially expressed in a manner specific to metastatic site, and stromal monoamine oxidase B expression was correlated with prognosis.
url https://doi.org/10.1177/1010428318776822
work_keys_str_mv AT yoonjincha sitespecificexpressionofamineoxidasesinbreastcancermetastases
AT wooheejung sitespecificexpressionofamineoxidasesinbreastcancermetastases
AT jaseungkoo sitespecificexpressionofamineoxidasesinbreastcancermetastases
_version_ 1721490436459069440